Lixisenatide added to basal insulin reduces glycaemic variability in patients with type 2 diabetes mellitus

Background and aims: This analysis evaluated the impact on glycaemic variability (GV) of lixisenatide (LIXI) vs placebo (PBO) as add-on to basal insulin ± oral antidiabetes drugs (OADs) in patients with type 2 diabetes mellitus (T2DM). Materials and methods: Patient-level data from GetGoal-L, GetGoa...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2014

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/25608

Acceso en línea:

https://doi.org/10.1007/s00125-014-3355-0
https://repository.urosario.edu.co/handle/10336/25608

Palabra clave:

Animals
Diabetes Mellitus
Humans

Rights

License

http://purl.org/coar/access_right/c_14cb